Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Trial Updates and Chronic Lymphocytic Leukemia

View overview page
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter’s transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
1:19
The prognostic value of MRD in CLL
Joanna Rhodes • 11 Dec 2023
3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
1:13
Dual-targeted regimens for the treatment of CLL: anti-CD20 antibodies, BTKi, and BCL2i
Chaitra Ujjani • 11 Dec 2023
1:21
MRD dynamics between arms of the FLAIR trial: comparing PB and BM MRD in patients with CLL
Talha Munir • 12 Dec 2023
1:35
55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL
Talha Munir • 12 Dec 2023
2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
1:18
Investigating acquired mutations in patients with R/R CLL who progressed in the ALPINE study
Jennifer Brown • 11 Dec 2023
1:55
Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trial
Jennifer Brown • 11 Dec 2023
1:43
Extended follow-up of the ALPINE trial: superior outcomes with zanubrutinib in R/R CLL/SLL
Jennifer Brown • 11 Dec 2023
1:42
What’s on the horizon for patients with Richter’s transformation?
Adam Kittai • 10 Dec 2023
2:18
Efficacy of subsequent therapies for CLL patients treated in the MURANO trial
John Seymour • 8 Dec 2023
2:25
The safety & efficacy of copanlisib + nivolumab in patients with RT and tNHL: a chemo-free approach
Alexey Danilov • 8 Dec 2023
1:01
Pirtobrutinib, venetoclax, and rituximab in the treatment of R/R CLL: insights from the BRUIN trial
Catherine Coombs • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals